A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
Clinical trial NCT06042894 · RECRUITING
Trial details
- NCT number
- NCT06042894
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-12
- Primary completion
- 2026-12-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.